Research Analysts Set Expectations for Geron FY2026 Earnings

Geron Co. (NASDAQ:GERN) – B. Riley lifted their FY2026 earnings per share estimates for shares of Geron in a report released on Thursday, November 7th. B. Riley analyst K. Patel now forecasts that the biopharmaceutical company will earn $0.19 per share for the year, up from their previous estimate of $0.15. The consensus estimate for Geron’s current full-year earnings is ($0.34) per share.

Geron (NASDAQ:GERN) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. The business had revenue of $28.27 million during the quarter, compared to analysts’ expectations of $18.97 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.10%. Geron’s revenue for the quarter was up 17138.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.08) earnings per share.

A number of other analysts have also issued reports on GERN. Leerink Partners began coverage on Geron in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 target price on the stock. StockNews.com raised shares of Geron to a “sell” rating in a research report on Monday, August 5th. Scotiabank began coverage on shares of Geron in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 price target for the company. Wedbush restated an “outperform” rating and set a $8.00 price objective on shares of Geron in a report on Thursday, August 8th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Geron in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.05.

Geron Stock Down 3.1 %

GERN stock opened at $4.12 on Monday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.61 and a quick ratio of 3.60. The company has a 50-day moving average of $4.30 and a two-hundred day moving average of $4.32. The stock has a market capitalization of $2.48 billion, a price-to-earnings ratio of -12.88 and a beta of 0.52. Geron has a 52-week low of $1.64 and a 52-week high of $5.34.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. National Bank of Canada FI boosted its stake in Geron by 1,200.0% in the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 6,000 shares during the period. Crewe Advisors LLC boosted its position in shares of Geron by 870.0% in the first quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 8,700 shares during the period. Kingsview Wealth Management LLC acquired a new position in shares of Geron in the first quarter valued at about $34,000. American Trust bought a new position in Geron during the first quarter worth about $38,000. Finally, Rovin Capital UT ADV acquired a new stake in Geron in the 3rd quarter worth about $62,000. 73.71% of the stock is owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.